Key regions: United States, Spain, Europe, Thailand, Canada
The Pharmaceutical Cannabis market in Southern Asia is experiencing significant growth and development driven by changing customer preferences, evolving trends, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Customers in Southern Asia are increasingly turning to Pharmaceutical Cannabis products due to growing awareness of their potential health benefits and therapeutic properties. The shift towards natural remedies and alternative medicine is influencing consumer choices, leading to a rising demand for Pharmaceutical Cannabis products in the region.
Trends in the market: In countries like India and Sri Lanka, there is a noticeable trend towards the legalization and medical use of Cannabis products, including Pharmaceutical Cannabis. This trend is driven by changing regulatory environments and a growing body of research supporting the efficacy of Cannabis-based treatments. As a result, more pharmaceutical companies are entering the market and offering a variety of Cannabis-derived products to cater to the increasing demand.
Local special circumstances: Southern Asia presents a unique set of circumstances that are contributing to the development of the Pharmaceutical Cannabis market in the region. For instance, the cultural acceptance of certain Cannabis products for medicinal purposes in countries like Nepal and Bhutan is shaping consumer attitudes and consumption patterns. Additionally, the presence of a large population with diverse healthcare needs is creating opportunities for Pharmaceutical Cannabis companies to introduce specialized products tailored to local preferences.
Underlying macroeconomic factors: The economic landscape in Southern Asia is also playing a role in the growth of the Pharmaceutical Cannabis market. Factors such as increasing disposable income levels, expanding healthcare infrastructure, and rising investments in research and development are creating a conducive environment for the pharmaceutical industry, including companies focusing on Cannabis-based products. Moreover, the potential for export opportunities and international collaborations is further driving the expansion of the Pharmaceutical Cannabis market in the region.
Data coverage:
Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.Modeling approach / Market size:
Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.Additional Notes:
The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
